Let's Chat About...Gene Independent Therapy for IRDs
June 21, 2022 @ 1:00PM — 2:00PM Eastern Time (US & Canada) Add to Calendar
Join our conversation on Gene Independent Therapy for IRDs with Daniel Chung
Let’s Chat About … Gene Independent Therapy for IRDs
Join our Zoom with Daniel Chung, DO, MA, Chief Medical Officer for SparingVision. Dan will discuss gene therapy highlighting their gene independent approaches using rod derived cone viability factor and the GIRK strategies.
About Daniel Chung
Dr. Chung is the Chief Medical Officer for SparingVision, an ocular genomic medicine company, focusing on gene agnostic gene therapy and CRISPR gene editing approaches to combat blinding diseases. Prior to his recruitment to SparingVision, Dr. Chung was the Ophthalmology Therapeutic Leader for Spark Therapeutics, Where he led the medical affair group and contributed to areas of clinical development and operations, marketing, commercial, patient advocacy, pre-clinical research and development and business development. Dr. Chung was intimately involved with the development of Luxturna, the first gene therapy approved by the FDA and EMA for use in a blinding genetic disease.
Prior to joining Spark Therapeutics, at the Scheie Eye Institute, University of Pennsylvania, working in retinal gene therapy. Also serving as a sub-PI on the RPE65 gene therapy clinical trial at the Children’s Hospital of Philadelphia (CHOP), and made major contribution to the development of the Phase 3 MLMT novel endpoint, was PI of the MLMT study, and the RPE65 Natural History Study. He completed his ophthalmology residency Summa Health Systems in Akron, Ohio. He then completed fellowships in pediatric ophthalmology and ocular genetics research at the Cole Eye Institute at the Cleveland Clinic, and in retinal gene therapy at the National Eye Institute/NIH in Bethesda, MD
About the "Let's Chat About..." Web Series
